Jiang Haihui, Zhang Zhe, Ren Xiaohui, Zeng Wei, Jia Wenqing, Wang Junmei, Lin Song
Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, China National Clinical Research Center for Neurological Diseases, Center of Brain Tumor, Beijing Institute for Brain Disorders and Beijing Key Laboratory of Brian Tumor, Beijing, 100050, People's Republic of China.
J Neurooncol. 2014 Dec;120(3):607-14. doi: 10.1007/s11060-014-1593-0. Epub 2014 Aug 24.
The subjectivity in pathological diagnosis of anaplastic oligoastrocytoma (AOA) and uncertainty in designation of glioblastoma with oligodendroglioma component (GBMO) were two major dilemmas which puzzled neuro-pathologists and neurosurgeons. The present study was designed to project a molecular classification scheme based on the status of chromosome 1p and 19q. Patients (n = 117) with histological diagnosis of primary high-grade oligodendroglial tumors (HGOs) enrolled in the study. Fluorescence in situ hybridization (FISH) for chromosomes 1p and 19q was performed. Univariate analysis showed that higher tumor grade, 1p/19q maintenance and 1q/19p co polysomy were confirmed as risk factors in HGOs (P < 0.01). Accordingly, patients with HGOs were divided into four subtypes which conferred remarkably distinct prognosis based on the number of risk factors (0 risk factor: HGOs-1, 1 risk factor: HGOs-2, 2 risk factors: HGOs-3, 3 risk factors: HGOs-4). Cox regression model revealed that the tumor grade was no longer independently associated with survival, while the molecular classification scheme showed a marked prognostic significance (HR = 0.359, 95 % CI 0.261-0.494, P < 0.001 for progression-free survival (PFS); HR = 0.393, 95 % CI 0.283-0.546, P < 0.001 for overall survival (OS)). The classification scheme incorporating traditional pathology with molecular information can be served as a supplement of the current WHO classification system and contribute to the personalized treatment decision-making.
间变性少突星形细胞瘤(AOA)病理诊断中的主观性以及伴少突胶质细胞瘤成分的胶质母细胞瘤(GBMO)命名的不确定性是困扰神经病理学家和神经外科医生的两大主要难题。本研究旨在基于1号染色体和19号染色体状态设计一种分子分类方案。纳入本研究的患者(n = 117)组织学诊断为原发性高级别少突胶质细胞瘤(HGO)。对1号染色体和19号染色体进行荧光原位杂交(FISH)检测。单因素分析显示,更高的肿瘤分级、1p/19q保留和1q/19p共多体性被确认为HGO的危险因素(P < 0.01)。据此,根据危险因素数量将HGO患者分为四个亚型,其预后明显不同(0个危险因素:HGO-1,1个危险因素:HGO-2,2个危险因素:HGO-3,3个危险因素:HGO-4)。Cox回归模型显示,肿瘤分级不再与生存独立相关,而分子分类方案具有显著的预后意义(无进展生存期(PFS):HR = 0.359,95%CI 0.261 - 0.494,P < 0.001;总生存期(OS):HR = 0.393,95%CI 0.283 - 0.546,P < 0.001)。将传统病理学与分子信息相结合的分类方案可作为现行世界卫生组织(WHO)分类系统的补充,有助于个性化治疗决策。